3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
2
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Dermatologic
6
Plasma cell
2
Other hematologic neoplasm
2
Gastrointestinal
2
CNS
2
Lymphoid
1
Gynecologic
1
Breast
1
Conditions
Hematologic Neoplasms
1
Endometrial Neoplasms
1
Colonic Neoplasms
1
Basal Cell Nevus Syndrome
1
Interventions
Paclitaxel
233
Carboplatin
217
Bevacizumab
139
Cisplatin
136
pembrolizumab
89
Gemcitabine
69
olaparib
54
Docetaxel
47
Topotecan
44
Radiotherapy
43
liposomal doxorubicin
41
Taxes
41
niraparib
38
Cyclophosphamide
36
Doxorubicin
30
Drug Therapy
29
Letrozole
28
Nivolumab
27
Magnetic Resonance Spectroscopy
25
Immunoglobulin G
25
Disulfides
24
Oxaliplatin
23
Albumin-Bound Paclitaxel
23
durvalumab
22
apatinib
21
Etoposide
21
Brachytherapy
21
lenvatinib
20
camrelizumab
20
Specimen Handling
20
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
sonidegib
×
Gynecologic
×
Clear all
NCT02002689
2016-05-02
SIGNATURE
Novartis
Phase 2
Terminated
10 enrolled
9 charts